Live Breaking News & Updates on Brokerage nomura

Stay informed with the latest breaking news from Brokerage nomura on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Brokerage nomura and stay connected to the pulse of your community

Hot Stocks: Brokerages on RIL, Entero Healthcare, Natco Pharma and Persistent Systems

Brokerage Nomura upheld a neutral rating on Persistent Systems, while Investec continues to advocate a buy stance on Natco Pharma and has initiated a buy recommendation on Entero Healthcare. Conversely, CLSA has downgraded RIL to an outperform rating.

Natco-pharma , Brokerage-nomura , Persistent-systems , Entero-healthcare ,

Lupin gets target hike from Nomura to Rs 1,949 on growth potential in US products

Nomura suggests that the launch of US products and stringent cost control measures could exceed current earnings estimates. Additionally, Lupin has potential limited competition opportunities in FY25 with products like gOracea, gMyrbetriq, and gSlynd, pending a favorable verdict.

Mayne-pharma , Brokerage-nomura , Markets-news , Quity-markets , Uzzing-stocks , Upin ,

Hot Stocks: Brokerage firms on HDFC Bank, Dalmia Bharat, SBI Life and IOC

Macquarie maintained outperform rating on HDFC Bank with target price of Rs 2075. The bank is consolidating, focusing on NIMs. Deposit growth must exceed loan growth by 400bps over next 3 years for pre-merger NIMs. CLSA raised target price for SBI Life to Rs 1730, it has limited impact of surrender value regulations. SBI's wide presence gives it an advantage. CLSA upgraded Dalmia Bharat to buy with target price of Rs 2700. Q3 Ebitda in line with estimates. Nomura maintained neutral rating on IOC with target price of Rs 105, Q3 results above estimates.

Dalmia-bharat , Brokerage-nomura , Hdfc-bank , Sbi-life , Ioc , Stock-market ,

Hot Stocks: Brokerage view on Fortis Healthcare, Cello World, HPCL and Emami

Nomura maintained a buy rating on Fortis Healthcare but raised the target to Rs 475 from Rs 388 earlier. There are adequate levers in place to deliver margin expansion. The global investment bank sees the hospital segment's EBITDA margin to improve to 20.2% in FY25 from 16.9% in FY23.

China , India , Morgan-stanley , Brokerage-nomura , Fortis-healthcare , Cello-world , Hpcl , Stock-recommendations , Stock-ideas , Emami ,

Nomura: Nomura upgrades India to overweight; ICICI, Axis and RIL among top picks

"We see recent softness driven by higher oil prices as an opportunity to raise exposure," said Nomura's analysts including Chetan Seth, Anshuman Agarwal, and Ankit Yadav in the firm's Asia strategy note to clients. "While this weakness may persist in the near term, thus presenting even better timing, we think the window of opportunity might not be open for too long."

China , Mumbai , Maharashtra , India , Chetan-seth , Anshuman-agarwal , Uno-minda , Ankit-yadav , Reliance-industries , Axis-bank , Medplus-health , Nomura-upgrades-india